T. Rowe Price Investment Management
CAI

T. Rowe Price Investment Management’s Caris Life Sciences CAI Stock Holding History

T. Rowe Price Investment Management’s Portfolio CAI Stock Details CAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$99.9M Sell
5,588,257
-3,617,702
-39% -$79.1M 0.07% 248
2025
Q4 		$248M Buy
9,205,959
+1,180,200
+15% +$33.2M 0.16% 148
2025
Q3 		$243M Buy
8,025,759
+721,772
+10% +$23M 0.15% 153
2025
Q2 		$195M Buy
+7,303,987
New +$197M 0.12% 180

Other funds holding CAI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JHWEPV
J. H. Whitney Equity Partners VI New Canaan, Connecticut $326M AUM
SSP
Sixth Street Partners Dallas, Texas $711M AUM 9.3% 1-Year Est. Return
Coatue Management
Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

T. Rowe Price Investment Management's CAI Position: Q1 2026 in Review

T. Rowe Price Investment Management reduced its Caris Life Sciences (CAI) stake by 39% in Q1 2026, selling an estimated $79.1M and leaving 5,588,257 shares worth $99.9M. The position accounts for 0.07% of the portfolio, ranked #248.

T. Rowe Price Investment Management first reported a position in CAI in Q2 2025 and has held it in 4 quarters since. The position peaked at $248M in Q4 2025. 202 funds tracked by Wall St. Rank hold CAI as of Q1 2026.

  • T. Rowe Price Investment Management held 5,588,257 shares of Caris Life Sciences worth $99.9M as of Q1 2026.
  • T. Rowe Price Investment Management sold 3,617,702 Caris Life Sciences shares in Q1 2026, an estimated $79.1M.
  • Caris Life Sciences made up 0.07% of T. Rowe Price Investment Management's portfolio in Q1 2026, its #248 holding.
  • T. Rowe Price Investment Management first reported a position in Caris Life Sciences in Q2 2025 and has held it in 4 quarters since.
  • T. Rowe Price Investment Management's Caris Life Sciences position peaked at $248M in Q4 2025.
  • 202 funds tracked by Wall St. Rank held Caris Life Sciences as of Q1 2026.

Based on T. Rowe Price Investment Management's 13F filing for Q1 2026, filed 15 May 2026.